Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
Abstract This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer...
Guardado en:
Autores principales: | , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7d32e5f6f02144ce9a5f775eb813f943 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:7d32e5f6f02144ce9a5f775eb813f943 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:7d32e5f6f02144ce9a5f775eb813f9432021-12-02T11:39:44ZReal-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands10.1038/s41598-021-85696-32045-2322https://doaj.org/article/7d32e5f6f02144ce9a5f775eb813f9432021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85696-3https://doaj.org/toc/2045-2322Abstract This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer (NSCLC) in 2015–2018 in six Dutch large teaching hospitals (Santeon network) were identified and followed-up from date of diagnosis until death or end of data collection. Progression-free survival (PFS) and overall survival (OS) from first-line (1L) pembrolizumab and second-line (2L) nivolumab were compared with clinical trial data by calculating hazard ratios (HRs). From 1950 diagnosed patients, 1005 (52%) started with any 1L treatment, of which 83 received pembrolizumab. Nivolumab was started as 2L treatment in 141 patients. For both settings, PFS times were comparable between real-world and trials (HR 1.08 (95% CI 0.75–1.55), and HR 0.91 (95% CI 0.74–1.14), respectively). OS was significantly shorter in real-world for 1L pembrolizumab (HR 1.55; 95% CI 1.07–2.25). Receiving subsequent lines of treatment was less frequent in real-world compared to trials. There is no EE gap for PFS from immunotherapy in patients with stage IV NSCLC. However, there is a gap in OS for 1L pembrolizumab. Fewer patients proceeding to a subsequent line of treatment in real-world could partly explain this.Christine M. Cramer-van der WelleMarjon V. VerschuerenMerel TonnBas J. M. PetersFranz M. N. H. SchramelOlaf H. KlungelHarry J. M. GroenEwoudt M. W. van de GardeThe Santeon NSCLC Study GroupNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Christine M. Cramer-van der Welle Marjon V. Verschueren Merel Tonn Bas J. M. Peters Franz M. N. H. Schramel Olaf H. Klungel Harry J. M. Groen Ewoudt M. W. van de Garde The Santeon NSCLC Study Group Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands |
description |
Abstract This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer (NSCLC) in 2015–2018 in six Dutch large teaching hospitals (Santeon network) were identified and followed-up from date of diagnosis until death or end of data collection. Progression-free survival (PFS) and overall survival (OS) from first-line (1L) pembrolizumab and second-line (2L) nivolumab were compared with clinical trial data by calculating hazard ratios (HRs). From 1950 diagnosed patients, 1005 (52%) started with any 1L treatment, of which 83 received pembrolizumab. Nivolumab was started as 2L treatment in 141 patients. For both settings, PFS times were comparable between real-world and trials (HR 1.08 (95% CI 0.75–1.55), and HR 0.91 (95% CI 0.74–1.14), respectively). OS was significantly shorter in real-world for 1L pembrolizumab (HR 1.55; 95% CI 1.07–2.25). Receiving subsequent lines of treatment was less frequent in real-world compared to trials. There is no EE gap for PFS from immunotherapy in patients with stage IV NSCLC. However, there is a gap in OS for 1L pembrolizumab. Fewer patients proceeding to a subsequent line of treatment in real-world could partly explain this. |
format |
article |
author |
Christine M. Cramer-van der Welle Marjon V. Verschueren Merel Tonn Bas J. M. Peters Franz M. N. H. Schramel Olaf H. Klungel Harry J. M. Groen Ewoudt M. W. van de Garde The Santeon NSCLC Study Group |
author_facet |
Christine M. Cramer-van der Welle Marjon V. Verschueren Merel Tonn Bas J. M. Peters Franz M. N. H. Schramel Olaf H. Klungel Harry J. M. Groen Ewoudt M. W. van de Garde The Santeon NSCLC Study Group |
author_sort |
Christine M. Cramer-van der Welle |
title |
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands |
title_short |
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands |
title_full |
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands |
title_fullStr |
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands |
title_full_unstemmed |
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands |
title_sort |
real-world outcomes versus clinical trial results of immunotherapy in stage iv non-small cell lung cancer (nsclc) in the netherlands |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/7d32e5f6f02144ce9a5f775eb813f943 |
work_keys_str_mv |
AT christinemcramervanderwelle realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT marjonvverschueren realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT mereltonn realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT basjmpeters realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT franzmnhschramel realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT olafhklungel realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT harryjmgroen realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT ewoudtmwvandegarde realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands AT thesanteonnsclcstudygroup realworldoutcomesversusclinicaltrialresultsofimmunotherapyinstageivnonsmallcelllungcancernsclcinthenetherlands |
_version_ |
1718395708844802048 |